Anticancer Evaluation of Novel Benzofuran–Indole Hybrids as Epidermal Growth Factor Receptor Inhibitors against Non-Small-Cell Lung Cancer Cells
Pharmaceuticals · 09.02.2024 · 17 (2) · 231
DOI: 10.3390/ph17020231 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 09.02.2024. Verfasst von Yechan Lee und 7 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy and Yonsei Institute of Pharmaceutical Sciences, Yonsei University, 85 Songdogwahak-ro, Yeonsu-gu, Incheon 21983, Republic of Kor…. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
The epidermal growth factor receptor (EGFR), also known as ErbB1 and HER1, belongs to the receptor tyrosine kinase family. EGFR serves as the primary driver in non-small-cell lung cancer (NSCLC) and is a promising therapeutic target for NSCLC. In this study, we synthesized a novel chemical library based on a benzofuran–indole hybrid scaffold and identified 8aa as a potent and selective EGFR inhibitor. Interestingly, 8aa not only showed selective anticancer effects against NSCLC cell lines, PC9, and A549, but it also showed significant inhibitory effects against the double mutant L858R/T790M EGFR, which frequently occurs in NSCLC. In addition, in PC9 and A549 cells, 8aa potently blocked the EGFR signaling pathway, cell viability, and cell migration. These findings suggest that 8aa, a benzofuran–indole hybrid derivative, is a novel EGFR inhibitor that may be a potential candidate for the treatment of NSCLC patients with EGFR mutations.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Pharmacy and Yonsei Institute of Pharmaceutical Sciences, Yonsei University, 85 Songdogwahak-ro, Yeonsu-gu, Incheon 21983, Republic of Korea.
- Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul 03722, Republic of Korea.
ORCID-Profile: Yechan Lee, Doona Song, So-Hyeon Park, Wan Namkung, Ikyon Kim
Förderung
- National Research Foundation of Korea
Zitieren
APA
Lee, Y., Lee, S., Lee, Y., Song, D., Park, S. H., Kim, J., Namkung, W., & Kim, I. (2024). Anticancer Evaluation of Novel Benzofuran–Indole Hybrids as Epidermal Growth Factor Receptor Inhibitors against Non-Small-Cell Lung Cancer Cells. Pharmaceuticals, 17(2), 231. https://doi.org/10.3390/ph17020231
Vancouver
Lee Y, Lee S, Lee Y, Song D, Park SH, Kim J, et al. Anticancer Evaluation of Novel Benzofuran–Indole Hybrids as Epidermal Growth Factor Receptor Inhibitors against Non-Small-Cell Lung Cancer Cells. Pharmaceuticals. 2024;17(2):231. doi:10.3390/ph17020231
BibTeX
@article{Lee2024,
author = {Lee, Yechan and Lee, Sunhee and Lee, Younho and Song, Doona and Park, So-Hyeon and Kim, Jieun and Namkung, Wan and Kim, Ikyon},
title = {Anticancer Evaluation of Novel Benzofuran–Indole Hybrids as Epidermal Growth Factor Receptor Inhibitors against Non-Small-Cell Lung Cancer Cells},
journal = {Pharmaceuticals},
year = {2024},
volume = {17},
number = {2},
pages = {231},
doi = {10.3390/ph17020231}
}
EUVIMED